- Home
- TPST vs XLO Comparison
TPST vs XLO Comparison
Compare TPST & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- XLO
- Stock Information
- Founded
- TPST 2011
- XLO 2016
- Country
- TPST United States
- XLO United States
- Employees
- TPST N/A
- XLO N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- XLO Health Care
- Exchange
- TPST Nasdaq
- XLO Nasdaq
- Market Cap
- TPST 33.0M
- XLO 35.7M
- IPO Year
- TPST N/A
- XLO 2021
- Fundamental
- Price
- TPST $10.16
- XLO $0.71
- Analyst Decision
- TPST Hold
- XLO Buy
- Analyst Count
- TPST 3
- XLO 2
- Target Price
- TPST $30.00
- XLO $3.00
- AVG Volume (30 Days)
- TPST 111.5K
- XLO 419.4K
- Earning Date
- TPST 08-11-2025
- XLO 08-14-2025
- Dividend Yield
- TPST N/A
- XLO N/A
- EPS Growth
- TPST N/A
- XLO N/A
- EPS
- TPST N/A
- XLO N/A
- Revenue
- TPST N/A
- XLO $15,001,000.00
- Revenue This Year
- TPST N/A
- XLO $300.08
- Revenue Next Year
- TPST N/A
- XLO $1.87
- P/E Ratio
- TPST N/A
- XLO N/A
- Revenue Growth
- TPST N/A
- XLO 536.45
- 52 Week Low
- TPST $5.35
- XLO $0.62
- 52 Week High
- TPST $20.67
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- TPST 72.60
- XLO 54.30
- Support Level
- TPST $6.96
- XLO $0.67
- Resistance Level
- TPST $10.90
- XLO $0.73
- Average True Range (ATR)
- TPST 0.63
- XLO 0.04
- MACD
- TPST 0.33
- XLO 0.01
- Stochastic Oscillator
- TPST 81.24
- XLO 82.36
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).